A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors

Trial Identifier: D7980C00001
Sponsor: MedImmune, LLC
NCTID:: NCT03530397
Start Date: April 2018
Primary Completion Date: December 2025
Study Completion Date: December 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
AU Melbourne, AU, 3004
AU Randwick, AU, 2031
ES A Coruna, ES, 15006
ES Barcelona, ES, 08028
ES Barcelona, ES, 08916
ES Barcelona, ES, 08035
ES Barcelona, ES, 08041
ES Barcelona, ES, 08003
ES Majadahonda, ES, 28222
ES Malaga, ES, 29010
ES Pamplona, ES, 31008
ES Valencia, ES, 46010
FR Bordeaux Cedex, FR, 33075
FR Lyon, FR, 69373
FR Villejuif Cedex, FR, 94805
IT Meldola, IT, 47014
IT Napoli, IT, 80131
IT Ravenna, IT, 48121
IT Roma, IT, 168
KR Cheongju-si, KR, 28644
KR Gyeonggi-do, KR, 13620
KR Incheon, KR, 21565
KR Seoul, KR, 05505
KR Seoul, KR, 03080
KR Seoul, KR, 03722
KR Seoul, KR, 06351
NL Amsterdam, NL, 1066 CX
PT Lisboa, PT, 1649-035
PT Porto, PT, 4200-072
TW Taichung, TW, 40705
TW Tainan, TW, 70403
TW Taipei, TW, 10048
US, MI Detroit, MI, US, 48202
US, North Carolina Chapel Hill, North Carolina, US, 27599
US, NY New York, NY, US, 10065
US, RI Providence, RI, US, 02903
US, TN Chattanooga, TN, US, 37404
US, TN Nashville, TN, US, 37203
US, VA Fairfax, VA, US, 22031